Completed Clinical Trials

As these trials move through the approval pipeline, they complete various phases before moving on to the next phase. Here’s the latest on the conditions for which we have completed specific phases, as well as information on our planned next steps.


Canine atopic dermatitis (CAD) is an allergic skin condition that affects more than 13 million dogs. Current therapies are either daily or monthly administration. Gallant’s cell therapy is designed to have a longer duration of action. Early pilot data in a placebo-controlled clinical trial suggest dogs may get a year or more of relief from a one-time therapy delivered IV.

Gallant has completed the phase one proof of concept and plans to start the phase two placebo-controlled large trial in 2025.

Interested in Becoming a Host Site for Future Trials?